Am J Surg Pathol
- EUSCHER ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, et al
Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study
of 33 Cases.
Am J Surg Pathol. 2023;47:635-648.
BMC Cancer
- FANALE D, Brando C, Corsini LR, Cutaia S, et al
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal
carcinomatosis improve prognosis of women with advanced high-grade serous ovarian
cancer.
BMC Cancer. 2023;23:437.
Cancer Chemother Pharmacol
- HU C, Zhang Y, Pei T, Liu P, et al
Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy
volunteers.
Cancer Chemother Pharmacol. 2023;91:523-529.
Cancer Res
- PETRELLI A, Rizzolio S, Pietrantonio F, Bellomo SE, et al
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
Cancer Res. 2023 May 2:OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620.
Clin Cancer Res
- GONZALEZ-OCHOA E, Oza AM
An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian
cancer.
Clin Cancer Res. 2023 May 16:CCR-23-0652. doi: 10.1158/1078-0432.CCR-23-0652.
Gynecol Oncol
- FENG Z, Fu Y, Li R, Li H, et al
Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of
epithelial ovarian cancer patients.
Gynecol Oncol. 2023;174:142-147.
- WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian
cancer: Tumor-First or Germline-First?
Gynecol Oncol. 2023;174:121-128.
- NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
Tissue factor as a novel diagnostic target for early detection of ovarian cancer
using ultrasound microbubbles.
Gynecol Oncol. 2023;173:138-150.
- BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative
to improve patient receipt of cancer genetics services at five health systems.
Gynecol Oncol. 2023;172:106-114.
- BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
HER2+ endometrioid endometrial cancer possesses distinct molecular and
immunologic features associated with a more active immune microenvironment and
worse prognosis.
Gynecol Oncol. 2023;172:98-105.
- AREND R, Dholakia J, Castro C, Matulonis U, et al
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2
basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol. 2023;172:82-91.
- OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
What's in it for me?: A value assessment of gynecologic cancer clinical trials
for Black women.
Gynecol Oncol. 2023;172:29-35.
Histopathology
- MIRKOVIC J, Olkhov-Mitsel E, Amemiya Y, Al-Hussaini M, et al
Mesonephric-like adenocarcinoma of the female genital tract: novel observations
and detailed molecular characterisation of mixed tumours and mesonephric-like
carcinosarcomas.
Histopathology. 2023;82:978-990.
J Clin Oncol
- KINNEY AY, Walters ST, Lin Y, Lu SE, et al
Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk
Communication and Navigation Intervention: Large Effect Size but Room to Grow.
J Clin Oncol. 2023;41:2767-2778.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016